Issa GC, Larson RA, Hughes TP, Hochhaus A, Takahashi N, Bombaci F, Wang J, Kim D-W, Kim DDH, Mayer J, Goh Y-T, le Coutre P, Kim I, Etienne G, Andorsky D, Gu E, Zhang Y, McCulloch T, Agrawal N, Jinwal R, Damon A, Sadek I, Cortes JE. Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia. haematol [Internet]. 2020Sep.10 [cited 2026Jul.9];. Available from: https://haematologica.org/article/view/14262